CAR-T(CAR-T)细胞疗法在非肿瘤性疾病中的应用
Chimeric antigen receptor T (CAR-T) cell therapy in non-oncological diseases.
CAR-T(CAR-T)细胞在血液系统恶性肿瘤中的应用推动了这种免疫治疗形式的显著进展。
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
英文原题:GSNOR overexpression enhances CAR-T cell stemness and anti-tumor function by enforcing mitochondrial fitness.
GSNOR overexpression enhances CAR-T cell stemness and anti-tumor function by enforcing mitochondrial fitness.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
CAR-T(CAR-T)细胞已成为治疗复发/难治性淋巴瘤和白血病患者的一种有前景疗法,但并非所有接受治疗者都能获得持久缓解。体内扩增能力有限以及活化后记忆分化不足,是CAR-T 疗效未达最佳的主要原因。nitric oxide(一氧化氮,NO)在调节线粒体动态和T细胞活化方面发挥多种作用,但其对CAR-T 细胞持久性和抗肿瘤效能的影响尚不清楚。
本研究发现,CAR持续信号不仅促进NO过量生成,还抑制T细胞中S-亚硝基谷胱甘肽还原酶(GSNOR)的表达;二者共同导致蛋白质S-亚硝基化增加,进而损害线粒体适应性并削弱T细胞干性。有意思的是,强制表达GSNOR可促进免疫活化后CAR-T 细胞向记忆表型分化,使其更能抵抗线粒体功能障碍,并进一步增强体外及小鼠肿瘤模型中的CAR-T 细胞扩增和抗肿瘤能力。
因此,本研究揭示NO在限制CAR-T 细胞持久性和功能方面的关键作用,并指出过表达GSNOR可能有助于对抗NO应激,使患者获得更持久的CAR-T 治疗保护。
Chimeric antigen receptor-T (CAR-T) cell has been developed as a promising agent for patients with refractory or relapsed lymphoma and leukemia, but not all the recipients could achieve a long-lasting remission. The limited capacity of in vivo expansion and memory differentiation post activation is one of the major reasons for suboptimal CAR-T therapeutic efficiency. Nitric oxide (NO) plays multifaceted roles in mitochondrial dynamics and T cell activation, but its function on CAR-T cell persistence and anti-tumor efficacy remains unknown.
Herein, we found the continuous signaling from CAR not only promotes excessive NO production, but also suppressed S-nitrosoglutathione reductase (GSNOR) expression in T cells, which collectively led to increased protein S-nitrosylation, resulting in impaired mitochondrial fitness and deficiency of T cell stemness.
Intriguingly, enforced expression of GSNOR promoted memory differentiation of CAR-T cell after immune activation, rendered CAR-T better resistance to mitochondrial dysfunction, further enhanced CAR-T cell expansion and anti-tumor capacity in vitro and in a mouse tumor model.
Thus, we revealed a critical role of NO in restricting CAR-T cell persistence and functionality, and defined that GSNOR overexpression may provide a solution to combat NO stress and render patients with more durable protection from CAR-T therapy.
在 PubMed 查看 → 出版商原文(DOI) 全文 PDF(PMC)· 可下载 治疗专题与资料阅读指南 资料来源与翻译说明 报告译文或资料问题 →
MEMBER ACCOUNT
登录成功会直接打开下一页。